Life expectancy of adult liver allograft recipients in the UK

Barber, Kerri; Blackwell, Joanne; Collett, David; Neuberger, James

doi:10.1136/gut.2006.093195

Cited by 77 publications

(49 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study provides further evidence that late mortality is not improving in liver transplant recipients (1,2). The death rate after 1 year in this cohort of UK transplant recipients did not improve with time and was more than twice the unadjusted death rate in the United Kingdom A Cox regression analysis demonstrated that donor age, recipient age, recipient gender, and cause of liver disease were not significant confounding variables for survival according to era of transplantation.…”

Section: Discussionmentioning

confidence: 70%

The Pattern of Late Mortality in Liver Transplant Recipients in the United Kingdom

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 70%

The Pattern of Late Mortality in Liver Transplant Recipients in the United Kingdom

et al. 2011

View full text Add to dashboard Cite

show abstract

“…3 Although a recent study reported an overall life expectancy of 22.2 years for adult LT recipients, the true ceiling for patient survival and allograft longevity in children who have undergone LT remains unknown and is likely higher. 4,5 Thus, the focus of post-LT care in children has shifted to encompass consequences related to the post-transplant course. Current knowledge dictating lifelong treatment with immunosuppressive medications has particular impact for pediatric patients, given that many children will live long enough to potentially develop end-organ damage.…”

mentioning

confidence: 99%

Health Status of Children Alive 10 Years after Pediatric Liver Transplantation Performed in the US and Canada: Report of the Studies of Pediatric Liver Transplantation Experience

Alonso

Bucuvalas

et al. 2012

The Journal of Pediatrics

228

235

View full text Add to dashboard Cite

Objectives To determine clinical and health-related quality of life outcomes, and to derive an “ideal” composite profile of children alive 10 years after pediatric liver transplantation (LT) performed in the US and Canada. Study design This was a multicenter cross-sectional analysis characterizing patients enrolled in the Studies of Pediatric Liver Transplantation database registry who have survived >10 years from LT. Results A total of 167 10-year survivors were identified, all of whom received daily immunosuppression therapy. Comorbidities associated with the post-LT course included post-transplantation lymphoproliferative disease (in 5% of patients), renal dysfunction (9%), and impaired linear growth (23%). Health-related quality of life, as assessed by the PedsQL 4.0 Generic Core Scales, revealed lower patient self-reported total scale scores for 10-year survivors compared with matched healthy children (77.2 ± 12.9 vs 84.9 ± 11.7; P < .001). At 10 years post-LT, only 32% of patients achieved an ideal profile of a first allograft stable on immunosuppression monotherapy, normal growth, and absence of common immunosuppression-induced sequelae. Conclusion Success after pediatric LT has moved beyond patient survival. Availability of an ideal composite profile at follow-up provides opportunities for patients, families, and healthcare providers to identify broader sets of outcomes at earlier stages, ultimately contributing to improved outcomes after pediatric LT.

show abstract

“…Liver transplantation is an effective treatment for patients with end-stage disease, giving an average of 17-22 years of additional life [2,3] . Access to liver transplantation is limited by donor availability; several innovations, including split liver, living donor transplantation, non-heart beating donation (NHBD) and the expansion of the donor criteria, have been attempted to tackle this disparity [4] .…”

Section: Ischemia-reperfusion Injurymentioning

confidence: 99%

Heme oxygenase system in hepatic ischemia-reperfusion injury

Richards

Wigmore²,

Devey³

2010

WJG

View full text Add to dashboard Cite

Hepatic ischemia-reperfusion injury (IRI) limits access to transplantation. Heme oxygenase-1 (HO-1) is a powerful antioxidant enzyme which degrades free heme into biliverdin, free iron and carbon monoxide. HO-1 and its metabolites have the ability to modulate a wide variety of inflammatory disorders including hepatic IRI. Mechanisms of this protective effect include reduction of oxygen free radicals, alteration of macrophage and T cell phenotype. Further work is required to understand the physiological importance of the many actions of HO-1 identified experimentally, and to harness the protective effect of HO-1 for therapeutic potential.

show abstract

Life expectancy of adult liver allograft recipients in the UK

Cited by 77 publications

References 11 publications

The Pattern of Late Mortality in Liver Transplant Recipients in the United Kingdom

The Pattern of Late Mortality in Liver Transplant Recipients in the United Kingdom

Health Status of Children Alive 10 Years after Pediatric Liver Transplantation Performed in the US and Canada: Report of the Studies of Pediatric Liver Transplantation Experience

Heme oxygenase system in hepatic ischemia-reperfusion injury

Contact Info

Product

Resources

About